Structured evidence table for Probiotic Womens Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Probiotic Womens Health Randomized Trial | Conclusion A high DI-GM score is significantly associated with a lower prevalence of osteoporosis in Chinese postmenopausal women, particularly when comparing the highest versus the lowest score categories. | 3 | Yin X (2026) | Dietary Index for Gut Microbiota and Osteoporosis Risk in Chinese Postmenopausal Women: A Case-Control Study. |
| Probiotic Womens Health Randomized Trial | The current study aimed to assess the association between the dietary index for gut microbiota (DI-GM) and osteoporosis in Chinese populations. | 3 | Yin X (2026) | Dietary Index for Gut Microbiota and Osteoporosis Risk in Chinese Postmenopausal Women: A Case-Control Study. |
| Probiotic Womens Health Randomized Trial | Methods We conducted a case-control study among 500 postmenopausal Chinese women (250 osteoporosis and 250 controls). | 3 | Yin X (2026) | Dietary Index for Gut Microbiota and Osteoporosis Risk in Chinese Postmenopausal Women: A Case-Control Study. |
| Probiotic Womens Health Randomized Trial | This comprehensive review systematically examines the existing evidence regarding the putative influence of gut microbiota on SO risk in menopausal women via the modulation of estrogen metabolism, critically evaluates the underlying molecular mechanisms and methodological limitations, and explores potential translational applications. | 3 | Jin Yuanyuan (2026) | Gut Microbiota Has the Potential to Improve Sarcopenic Obesity in Menopausal Women by Regulating Estrogen |
| Probiotic Womens Health Randomized Trial | Emerging evidence suggests that probiotic interventions may confer beneficial effects across multiple estrogen deficiency-related pathologies, providing a mechanistic rationale for their broader application in postmenopausal women’s health. | 3 | Jin Yuanyuan (2026) | Gut Microbiota Has the Potential to Improve Sarcopenic Obesity in Menopausal Women by Regulating Estrogen |
| Probiotic Womens Health Randomized Trial | () Evidence hierarchy across menopause-related conditions, from strong (GSM) to emerging (sarcopenic obesity). | 3 | Jin Yuanyuan (2026) | Gut Microbiota Has the Potential to Improve Sarcopenic Obesity in Menopausal Women by Regulating Estrogen |
| Probiotic Womens Health Randomized Trial | 1 2 3 4 Figure 1 Sarcopenic obesity (SO), an emerging metabolic syndrome in postmenopausal women, is characterized by progressive loss of skeletal muscle mass and function coupled with abnormal visceral fat accumulation. | 3 | Jin Yuanyuan (2026) | Gut Microbiota Has the Potential to Improve Sarcopenic Obesity in Menopausal Women by Regulating Estrogen |
Source documents